AstraZeneca lists €2.55B euro notes in London
Rhea-AI Filing Summary
ASTRAZENECA PLC (AZN) reports that its wholly owned subsidiary AstraZeneca Finance LLC has had four euro-denominated bond series with an aggregate nominal amount of EUR 2.55 billion admitted to trading on the Main Market of the London Stock Exchange on 1 September 2026.
The notes comprise EUR 700 million 3.402% Notes due 1 March 2030, EUR 600 million 3.652% Notes due 1 September 2032, EUR 500 million 3.923% Notes due 1 September 2035, and EUR 750 million 4.169% Notes due 1 September 2038, all issued under a Base Prospectus dated 9 June 2026 and targeted at professional clients and eligible counterparties only.
Positive
- None.
Negative
- None.
Key Figures
Aggregate nominal amount of Notes: EUR 2.55 billion
2030 Notes nominal amount: EUR 700,000,000
2030 Notes coupon: 3.402 per cent.
+5 more
8 metrics
Aggregate nominal amount of Notes
EUR 2.55 billion
Four series of notes admitted to trading
2030 Notes nominal amount
EUR 700,000,000
3.402 per cent. Notes due 1 March 2030
2030 Notes coupon
3.402 per cent.
EUR 700,000,000 Notes due 1 March 2030
2032 Notes nominal amount
EUR 600,000,000
3.652 per cent. Notes due 1 September 2032
2035 Notes nominal amount
EUR 500,000,000
3.923 per cent. Notes due 1 September 2035
2038 Notes nominal amount
EUR 750,000,000
4.169 per cent. Notes due 1 September 2038
Date of admission to trading
1 September 2026
Admission of the four note series to the London Stock Exchange Main Market
Date of Base Prospectus
9 June 2026
Base Prospectus under which the securities have been issued
Key Terms
Base Prospectus, Regulated Market, EU MiFID II, eligible counterparties, +1 more
5 terms
Base Prospectus regulatory
"The base prospectus dated 9 June 2026 (the " Base Prospectus ")"
A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.
Regulated Market regulatory
"Admission to Trading on a Regulated Market (PRM) sourcebook 1.5.2"
A regulated market is an organized trading venue overseen by government or independent authorities that enforces rules on who can list, what information must be published, and how trades are executed. Think of it like a store that must pass safety inspections and display clear labels: the oversight promotes honesty, regular reporting, and fair access, which helps investors compare options, find buyers and sellers, and reduces the risk of fraud or hidden problems.
EU MiFID II regulatory
"EU MiFID II/UK MiFIR (Product Governance) - professionals and ECPs-only"
eligible counterparties regulatory
"target market (EU MiFID II product governance and MiFIR product governance) is eligible counterparties"
A regulatory category for counterparties—typically financial institutions, large corporates, or governments—deemed sophisticated enough to trade without the full set of investor protections given to retail clients. Think of it like a wholesale customer classification: eligible counterparties can access more complex products and faster execution but receive fewer disclosures and safeguards. Investors should care because deals with eligible counterparties can be quicker and cheaper, yet carry higher informational and risk responsibility.
PRIIPs key information document (KID) regulatory
"No EU PRIIPs key information document (KID) or UK PRIIPs key information document"
A PRIIPs Key Information Document (KID) is a short, standardized leaflet that explains the essential facts about complex packaged investment products for everyday investors. Like a nutrition label on food, it lays out what you might gain or lose, the main risks, and the costs in a simple, comparable way so buyers can quickly compare options and make informed choices before investing.
FAQ
What debt securities did AZN’s subsidiary have admitted to trading in September 2026?
AstraZeneca Finance LLC had four euro bond series admitted: EUR 700m 3.402% due 2030, EUR 600m 3.652% due 2032, EUR 500m 3.923% due 2035, and EUR 750m 4.169% due 2038, all on the Main Market of the London Stock Exchange.
What is the total nominal size of AstraZeneca (AZN)’s September 2026 euro bond admission?
The four bond series admitted to trading have an aggregate nominal amount of EUR 2.55 billion, comprising tranches of EUR 700 million, EUR 600 million, EUR 500 million, and EUR 750 million issued by AstraZeneca Finance LLC.
When were AstraZeneca (AZN)’s new euro notes admitted to trading?
The four euro-denominated note series issued by AstraZeneca Finance LLC were admitted to trading on the Main Market of the London Stock Exchange on 1 September 2026.
Are AstraZeneca (AZN)’s newly admitted euro notes available to retail investors?
No. The filing states the target market is eligible counterparties and professional clients only in the EEA and UK, and no EU or UK PRIIPs key information document has been prepared, so the notes are not available to retail investors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
